CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

upadacitinib

Last Updated: March 15, 2021
Result type: Reports
Project Number: SR0685-000
Product Line: Reimbursement Review

Generic Name: upadacitinib

Brand Name: Rinvoq

Manufacturer: AbbVie

Therapeutic Area: atopic dermatitis

Indications: ​Rinvoq is indicated for the treatment of adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. Rinvoq can be used with or without topical corticosteroids

Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: March 15, 2021

Call for patient/clinician input closed: May 7, 2021

Anticipated Date: April 13, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback